JP6811233B2 - Ｔｎｆアルファの修飾因子として有用な環状化合物 - Google Patents

Ｔｎｆアルファの修飾因子として有用な環状化合物 Download PDF

Info

Publication number
JP6811233B2
JP6811233B2 JP2018506125A JP2018506125A JP6811233B2 JP 6811233 B2 JP6811233 B2 JP 6811233B2 JP 2018506125 A JP2018506125 A JP 2018506125A JP 2018506125 A JP2018506125 A JP 2018506125A JP 6811233 B2 JP6811233 B2 JP 6811233B2
Authority
JP
Japan
Prior art keywords
phenyl
tetrahydrobenzo
cyclopropa
fluoro
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018506125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525377A (ja
JP2018525377A5 (enExample
Inventor
ハイ−ユン・シャオ
ティ・ジー・ムラリ・ダール
ビン・ジアン
ジンウー・ドワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2018525377A publication Critical patent/JP2018525377A/ja
Publication of JP2018525377A5 publication Critical patent/JP2018525377A5/ja
Application granted granted Critical
Publication of JP6811233B2 publication Critical patent/JP6811233B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018506125A 2015-08-03 2016-08-02 Ｔｎｆアルファの修飾因子として有用な環状化合物 Active JP6811233B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200415P 2015-08-03 2015-08-03
US62/200,415 2015-08-03
PCT/US2016/045104 WO2017023902A1 (en) 2015-08-03 2016-08-02 Cyclic compounds useful as modulators of tnf alpha

Publications (3)

Publication Number Publication Date
JP2018525377A JP2018525377A (ja) 2018-09-06
JP2018525377A5 JP2018525377A5 (enExample) 2019-08-15
JP6811233B2 true JP6811233B2 (ja) 2021-01-13

Family

ID=56610045

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506125A Active JP6811233B2 (ja) 2015-08-03 2016-08-02 Ｔｎｆアルファの修飾因子として有用な環状化合物

Country Status (13)

Country Link
US (1) US10335392B2 (enExample)
EP (1) EP3331889B1 (enExample)
JP (1) JP6811233B2 (enExample)
KR (1) KR102679517B1 (enExample)
CN (1) CN108137609B (enExample)
AU (1) AU2016301215A1 (enExample)
BR (1) BR112018001980A2 (enExample)
CA (1) CA2994703A1 (enExample)
EA (1) EA201890421A1 (enExample)
ES (1) ES2828696T3 (enExample)
IL (1) IL257159A (enExample)
MX (1) MX2018001173A (enExample)
WO (1) WO2017023902A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104293A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
US9856253B2 (en) 2015-04-17 2018-01-02 Abbvie, Inc. Tricyclic modulators of TNF signaling
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP4146626A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. CHEMOTHERAPEUTIC AGENTS BASED ON HETEROAROMATIC MACROCYCLIC ETHERS
PH12022552787A1 (en) 2020-05-05 2024-03-25 Nuvalent Inc Heteroaromatic macrocyclic ether chemotherapeutic agents
CA3231813A1 (en) 2021-10-01 2023-04-06 Sibao CHEN Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
AU2023320651A1 (en) * 2022-08-08 2025-02-27 Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. TGF-β INHIBITOR COMPOUND AND USE THEREOF

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5149386A (ja) * 1974-10-28 1976-04-28 Hitachi Ltd Shuchukanshiseigyohoho
AU741772B2 (en) 1997-02-25 2001-12-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
JPH11228539A (ja) * 1997-12-03 1999-08-24 Taisho Pharmaceut Co Ltd 含窒素四環性化合物
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
JPWO2003064422A1 (ja) 2002-01-31 2005-05-26 第一製薬株式会社 イミダゾ［１，２−ａ］ピリジン誘導体
AU2003298839A1 (en) 2002-12-03 2004-06-23 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
WO2009045174A1 (en) 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
ES2797523T3 (es) 2009-03-23 2020-12-02 Lilly Co Eli Agentes de obtención de imagen para detectar trastornos neurológicos
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
KR101669334B1 (ko) * 2013-09-30 2016-10-25 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 발광 소자
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
RU2695664C1 (ru) 2013-12-09 2019-07-25 Юсб Байофарма Спрл Производные имидазопиридина в качестве модуляторов активности tnf
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
BR112016013018A2 (pt) 2013-12-09 2017-08-08 Ucb Biopharma Sprl Derivados heteroaromáticos bicíclicos fundidos como moduladores de atividade de tnf
CN113248506A (zh) 2014-10-06 2021-08-13 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物及其治疗方法
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
EA032315B1 (ru) 2015-03-18 2019-05-31 Бристол-Маерс Сквибб Компани Замещенные трициклические гетероциклические соединения
KR102696304B1 (ko) 2015-03-18 2024-08-16 브리스톨-마이어스 스큅 컴퍼니 Tnf의 억제제로서 유용한 헤테로시클릭 화합물

Also Published As

Publication number Publication date
EP3331889B1 (en) 2020-09-23
US10335392B2 (en) 2019-07-02
CN108137609A (zh) 2018-06-08
JP2018525377A (ja) 2018-09-06
CN108137609B (zh) 2021-07-16
KR20180031773A (ko) 2018-03-28
US20180221344A1 (en) 2018-08-09
MX2018001173A (es) 2018-04-24
WO2017023902A1 (en) 2017-02-09
EA201890421A1 (ru) 2018-07-31
EP3331889A1 (en) 2018-06-13
KR102679517B1 (ko) 2024-06-27
BR112018001980A2 (pt) 2018-09-18
CA2994703A1 (en) 2017-02-09
AU2016301215A1 (en) 2018-03-22
IL257159A (en) 2018-03-29
ES2828696T3 (es) 2021-05-27

Similar Documents

Publication Publication Date Title
JP6811233B2 (ja) Ｔｎｆアルファの修飾因子として有用な環状化合物
JP7328995B2 (ja) Ｐｄ－ｌ１免疫調節剤としてのテトラヒドロ－イミダゾ［４，５－ｃ］ピリジン誘導体
WO2020259679A1 (zh) 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
JP6779899B2 (ja) Ｔｎｆ阻害剤として有用なヘテロ環式化合物
CN107635992B (zh) 用作tnf抑制剂的三环杂环化合物
WO2019079649A1 (en) SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE
EP4037677B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP6805172B2 (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
CN120225506A (zh) 桥环并哒嗪类化合物及其用途
CN109476638A (zh) 吡唑衍生物、其组合物及治疗用途
TW202134213A (zh) 具有水解磷脂酸受體作動活性之化合物及其醫藥用途
JP2019519576A (ja) ミエロペルオキシダーゼのマクロ環阻害剤
WO2017161145A1 (en) Triazolopyridine inhibitors of myeloperoxidase and/or epx
WO2025067411A1 (zh) 一种nek7抑制剂、药物组合物及其用途
TW202430525A (zh) Ｂｔｋ抑制劑
JP2025539873A (ja) Ｈｕｒ（ｅｌａｖｌ１）を調節するための化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190704

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201214

R150 Certificate of patent or registration of utility model

Ref document number: 6811233

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250